← All Marizyme, INC filings

Marizyme, INC 8-K filings

Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.

OTC.Pink
MRZM
Marizyme, INC
8-K: Marizyme, Inc. Initiates Asset Liquidation Process
Marizyme, Inc. has entered into an assignment for the benefit of creditors, effectively initiating a liquidation of all company assets.
OTC.Pink
MRZM
Marizyme, INC
8-K: Marizyme to Restate Prior Financial Statements Due to Accounting Errors
Marizyme, Inc. announced that it will restate its financial statements for the quarterly periods ended March 31, 2024, and June 30, 2024, due to material misstatements related to debt/equity transactions.
OTC.Pink
MRZM
Marizyme, INC
8-K: Marizyme Secures $1.25 Million Loan from Qualigen Therapeutics
Marizyme, Inc. has entered into a promissory note agreement with Qualigen Therapeutics, Inc., securing a $1.25 million loan with an 18% annual interest rate.
OTC.Pink
MRZM
Marizyme, INC
8-K: Marizyme Secures FDA Clearance for Room Temperature Storage of DuraGraft
Marizyme, Inc. has received FDA 510(k) clearance for its DuraGraft product to be stored at controlled room temperatures, eliminating the need for refrigerated storage.
OTC.Pink
MRZM
Marizyme, INC
8-K: Marizyme Inc. Director Resigns from Board
Julie Kampf resigned from Marizyme Inc.'s board of directors, effective January 31, 2024.